Therapy Areas: Inflammatory Diseases
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
9 October 2025 - US medical device company Autonomix Medical, Inc. (NASDAQ: AMIX) announced on Thursday that it has been granted a patent from the United States Patent and Trademark Office covering sy...
Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome
8 October 2025 - Precision diagnostic tests provider Oxford BioDynamics plc (AIM: OBD) on Wednesday announced the development of a first-in-class blood test for diagnosing Chronic Fatigue Syndrome (CF...
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
7 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of Verona Pharma plc (Nasda...
Avobis Bio's AVB-114 implantable cell therapy granted US FDA RMAT designation for Crohn's perianal fistulas
6 October 2025 - Avobis Bio LLC, a US-based clinical stage company developing implantable cell therapies, announced Friday that the US Food and Drug Administration (FDA) has granted Regenerative Medic...
Celltrion launches AVTOZMA IV in the United States following FDA approval
2 October 2025 - South Korea-based Celltrion, Inc., a global biopharmaceutical company, announced on Thursday that it has launched AVTOZMA (CT-P47, tocilizumab-anoh) intravenous formulation in the Uni...
Novartis to launch US direct-to-patient platform for Cosentyx
30 September 2025 - Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) announced on Monday that it plans to launch a direct-to-patient (DTP) platform in the United States which will...